Table 1.

Case report risk factors linked to quetiapine-associated QTc interval prolongation and TdP. Case 1 was also reported by Hustey [Hustey, 1999]. The case reports did not describe how the QTc interval was measured.

Case	Age (years), sex (M/F)	QTc (ms), TdP (yes/no)	Quetiapine (mg)	Risk factors
1 [Gajwani et al. 2000]	19M	710 No	9600	Quetiapine overdose, P4503A4 metabolic inhibitor (fluvoxamine), hypokalemia
2 [Beelen et al. 2001]	31F	537 No	2000	Female sex, quetiapine overdose, also taking low-dose risperidone
3 [Furst et al. 2002]	46F	569 No	800	Female sex, therapeutic quetiapine, possible competitive P4503A4 metabolic inhibition (lovastatin)
4 [Gupta et al. 2003]	50F	480 No	400	Female sex, therapeutic quetiapine, citalopram 40 mg/day
5 [Kurth and Maguire al. 2004]	14M	500 No	1900	Quetiapine overdose
6 [Vieweg et al. 2005]	45F	548 Yes	100	Female sex, therapeutic quetiapine, hypomagnesemia, hypocalcemia, also taking escitalopram, cardiac problems (hypertension, ventricular fibrillation)
7 [Strachan and Benoff, 2006]	41M	684 No	4500	Quetiapine overdose
8 [Bodmer et al. 2008]	34F	620 No	3000	Female sex, quetiapine overdose
9 [Digby et al. 2010]	58F	720 Yes	350	Female sex, therapeutic quetiapine, cardiac problems (hypertension, heart failure), also taking citalopram, hypokalemia
10 [Aghaienia et al. 2011]	63F	525 No	800	Female sex, therapeutic quetiapine, diabetes mellitus, past history of ziprasidone-induced QTc interval prolongation, hypokalemia
11 [Digby et al. 2011]	67F	610 Yes	200	Female sex, therapeutic quetiapine, cardiac problems (coronary artery disease, atrial fibrillation, prosthetic tricuspid valve replacement, epicardial pacemaker), hypokalemia, hypomagnesemia, escitalopram, furosemide
12 [Digby et al. 2011]	77F	529 Yes	25	Female sex, therapeutic quetiapine, cardiac (hypertension, aortic stenosis, and mitral stenosis), hypokalemia, hypomagnesemia, citalopram, amitriptyline, furosemide